T1	p 81 130	children and adolescents with autistic disorder .
T2	p 282 332	children and adolescents with autistic disorders .
T3	p 392 397	OLE )
T4	p 404 513	, patients ( 5-17 years of age , who completed the previous fixed-dose , 6 week , double-blind [ DB ] phase )
T5	p 805 871	Fifty-six ( 71 % ) out of 79 enrolled patients completed the OLE ;
T6	i 66 77	risperidone
T7	i 220 231	risperidone
T8	i 392 395	OLE
T9	i 539 550	risperidone
T10	i 724 735	risperidone
T11	i 1584 1595	risperidone
T12	i 1820 1841	risperidone treatment
T13	i 2000 2011	risperidone
T14	o 187 216	long-term safety and efficacy
T15	o 244 256	irritability
T16	o 736 756	's safety ; efficacy
T17	o 927 935	response
T18	o 950 974	or adverse events ( AE )
T19	o 1044 1049	) AEs
T20	o 1055 1073	increased appetite
T21	o 1093 1124	increased weight and vomiting (
T22	o 1146 1204	sedation , pyrexia , and upper respiratory tract infection
T23	o 1228 1243	nasopharyngitis
T24	o 1262 1288	and somnolence and fatigue
T25	o 1312 1330	Extrapyramidal AEs
T26	o 1381 1400	mean weight ( 11-15
T27	o 1403 1426	) and body mass index (
T28	o 1483 1489	weight
T29	o 1499 1564	. One potentially prolactin-related AE ( irregular menstruation )
T30	o 1629 1674	mean improvement in sleep visual analog scale
T31	o 1715 1751	improvement in efficacy scale scores
T32	o 2119 2153	irritability and related behaviors